New injection could fight stubborn joint infections after knee surgery

NCT ID NCT06889701

Recruiting now Disease control Sponsor: TenNor Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called TNP-2092, given as an injection into the knee joint, for people with infections after knee replacement surgery. The study includes 33 participants and compares the new drug to standard antibiotics. The main goal is to check safety and how the drug behaves in the body, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TNP-2092 (rifaquizinone) injection
What this could lead to: If it works, this could offer a new treatment option for stubborn joint infections after knee replacement, potentially reducing the need for long-term antibiotics.
What could go wrong: This is a very early phase 1/2 study with only 33 participants, so it is too soon to know if it works. The main focus is safety, and there may be side effects or no benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPROSTHETIC JOINT INFECTION (PJI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

periprosthetic joint infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPROSTHETIC JOINT INFECTION (PJI)

Contacts and locations

Locations

The First Affiliated Hospital of Xinjiang Medical University
RECRUITING

Ürümqi, Xinjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.